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Anticholinesterases (antiChEs) are used to treat Alzheimer’s disease. The comparative eﬀects of two antiChEs, methanesulfonyl
ﬂuoride (MSF) and donepezil, on the extracellular levels of ACh in the hippocampus were investigated by in vivo microdialysis
in freely moving rats. MSF at 1 and 2mg/kg produced a dose-dependent increase in ACh eﬄux from 10min to at least 3hrs
after injection. At 2mg/kg, the increase was still present at 24hr. Donepezil at 1mg/kg showed a similar but smaller eﬀect,
and, paradoxically, 2mg/kg showed no consistent eﬀect. MSF at 1 and 2mg/kg decreased acetylcholinesterase activity in the
hippocampus to 54.8 and 20.1% of control, respectively. These results suggest that MSF is a suitable candidate for the treatment of
Alzheimer’s disease.
1.Introduction
Alzheimer’s disease (AD) is a slowly progressive neurode-
generative illness characterized by the presence of senile
plaques containing β-amyloid protein (Aβ) in brain tissue,
tau-neuroﬁbrillary tangles in neurons and, the loss of
diﬀerenttransmitter-containingaxons,especiallycholinergic
nerves [1, 2]. Unfortunately, therapeutic strategies targeting
amyloid plaques with plaque-removing vaccines or gamma-
secretase modulators have been disappointing [3, 4].
It is generally accepted that progressive neurodegener-
ation of the cholinergic system underlies, at least in part,
the cognitive deterioration of Alzheimer’s disease (AD) [5–
7]. This hypothesis is supported by ﬁndings of encouraging
symptomatic improvements in clinical trials by the use of
AChE inhibitors [8, 9], theoretically by enhancing central
cholinergic function by permitting acetylcholine (ACh) to
remain in the synaptic cleft longer. Interestingly, some AChE
inhibitors have also been reported to be eﬀective also in
diminishing amyloid plaques [10, 11].
Methanesulfonyl ﬂuoride (MSF), a long-acting and
highly speciﬁc inhibitor of brain AChE [12, 13], has been
proposed as a safe and eﬀective palliative treatment for senile
dementia of the Alzheimer type [14]a sw e l la sam e t h o d
to attenuate stroke-induced deﬁcits in a simple learning and
memory task [13]. Therefore, the main aim of this study was
to compare MSF-induced increases in extracellular ACh in
the hippocampus, one of the target regions for the treatment
of AD, with the eﬀects of donepezil, a reference drug widely
used for symptomatic treatment of AD. For this purpose, the2 Advances in Pharmacological Sciences
presentstudywascarriedoutbymeasuringextracellularA Ch
in the hippocampus by in vivo microdialysis in freely moving
rats following administration of MSF and donepezil.
2.MaterialsandMethods
Male Sprague-Dawley rats (Japan SLC, Hamamatsu, Japan)
weighting 200–250g were housed one per cage under the
standard laboratory conditions (23 ± 1◦C, 55 ± 5% humid-
ity) with free access to standard pellet diet (MEQ, Oriental
Yeast Co., Tokyo) and drinking water ad libitum with lights
onat08:00andoﬀat20:00.Animalhandlingandprocedures
were conducted in accordance with the Animal Welfare Act
and with the Guide for the Care and Use of Laboratory
Animals approved by the Animal Experiment Committee in
Iwate University, Japan. Five rats were used in each group.
A l lr e a g e n t su s e dw e r ea n a l y t i c a lg r a d e .M S Fw a sp u r -
chased from Sigma-Aldrich (Milwaukee, USA) and (R,S-
1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)] methylpipe-
ridine hydrochloride (donepezil) was a gift from Eisai Co.,
Ltd., (Tokyo, Japan).
Microdialysis experiments were conducted according to
Hossain et al. [15]. Brieﬂy, the rats were anesthetized with
sodium pentobarbital (50mg/kg, i.p.) and then placed in a
stereotaxic apparatus (Kopf instrument). The microdialysis
guide cannula (AG-8, Eicom, Kyoto, Japan) was implanted
into the left hippocampus with the following coordination
(from the bregma): A − 5.8 mm, L +4 .8mm and, V − 4.5
mm. Following surgery, the animals were returned to their
home cage and allowed to recover for at least 3 days before
the beginning microdialysis.
ACh and choline content in the dialysate from the dif-
ferent animals were quantiﬁed by high-performance liq-
uid chromatograph (HPLC) with electrochemical detection
(ECD). The day of the experiment, the microdialysis probe
(A-1-8-02, Eicom, Kyoto) was carefully inserted into the
hippocampus through the guide cannula. The inlet of the
microdialysis probe was connected to a 2.5mL gastight
syringe and perfused with Ringer’s solution (NaCl 147mM,
KCl 4.0mM and, CaCl2 2.3mM) containing 1μM eserine
salicylate at a constant ﬂow 2μL/min using a microperfusion
pump, allowing the rats to move freely in a cubic Plexiglas
box (30cm × 30cm × 40cm).
The dialysate collected during the ﬁrst 30min was
discarded to ensure a stable baseline of ACh release. There-
after, 20μL samples of perfusate were collected at 10min
intervals. Upon collection, 20μLo f1μM ethylhomocholine
containing 10mM EDTA 2Na was added to each sample
as an internal standard. Levels of ACh and choline in the
dialysate (20μL/injection) were determined by electrochem-
ical detection with HPLC (Eicom, Kyoto, Japan) equipped
w i t ha ne n z y m ec o l u m n( A C - E N Z ,E i c o m ,K y o t o ,J a p a n ) .
A2 0μL sample of the perfusate/ethylhomocholine solution
was then injected into a HPLC equipped with ECD (HPLC-
ECD, Eicom, Kyoto) and enzyme column (AC-ENZ, Eicom,
Kyoto).
ACh and choline were separated on a cation exchange
column (EICOMPAK AC-GEL, Eicom, Kyoto) with sodium
lauryl sulfate (0.5mg/mL). The mobile phase consisted
of 0.05M phosphate buﬀer (Na2HPO4 12 H2O) pH 8.2
containing 0.13mM EDTA 2Na, 0.6mM tetramethylammo-
nium chloride and, 1.2mM SDS pumped at 1mL/min. The
retention times for choline and ACh were 7.3 and 13.2min,
respectively.
The basal eﬄu xw a sd e ﬁ n e da st h ea v e r a g eo u t p u to f
three samples prior to drug administration, and the results
were calculated as the percentage of the baseline choline and
ACh.
After establishing the basal eﬄux, the animals received
one of the following IP injections: MSF (1 or 2mg/kg)
or donepezil (1 or 2mg/kg) dissolved in vehicle (80μL
ethanol + 88μL Tween 20) and prepared to a 1mL total
volume with isotonic sodium chloride. All control animals
were injected with the same isotonic sodium chloride/vehicle
solution by the same route and volume (1mL/kg) as the
drug.
At the end of the microdialysis experiment, the rats were
euthanized with chloroform, the brains were removed, and
the position of the probe in the hippocampus was veriﬁed by
visual examination of 20μmf r o z e ns e c t i o n s .
For acetylcholinesterase assays, rats in a parallel group
received the same injections of MSF, donepezil, or vehicle
on the same schedule as the animals used in microdialysis
experiment. Three brain regions, hippocampus, striatum,
and cerebral cortex (cortex) were quickly dissected on ice at
180min and 24hr after injection of MSF or donepezil and
thenhomogenizedin0.1Mphosphatebuﬀersolution(0.1M
Na2PO4+0.1M KH2PO4, pH 8.0), followed by dilution with
the same buﬀer to 200, 400, and 200 times of tissue weight,
respectively, for the analysis of AChE activity by the method
of Ellman et al. [16] with 0.48mM acetylthiocholine iodide
as substrate for 2min at 25◦C using UV-240 spectropho-
tometer (Shimadzu Corporation, Kyoto, Japan) at 412nm.
The extracellular levels of ACh and choline from indi-
vidual rats were calculated relative to the mean basal release
(the average of three 10min sequential samples before drug
administration was taken as 100% basal release). Analysis of
variance, followed by Dunnett’s post hoc test for repeated
measurements (treatment versus time), was used to analyze
changes from ACh and choline baselines as well as for tests
of signiﬁcant diﬀerences over time. A level of P<0.05 was
taken to indicate a statistically signiﬁcant eﬀect.
3. Results
The injections of MSF and donepezil (1 and 2mg/kg
i.p.) did not produce any observable clinical signs or
symptoms in the rats. The basal rates of eﬄux from the
hippocampus of vehicle-only injected control rats were
5.2 ± 0.2pmol A Ch/10μL/10min and 180.8 ± 2.6pmol
choline/10μL/10min (n = 15). The response of ACh in
the hippocampus to vehicle treatment was not signiﬁcantly
diﬀerent throughout the experiment.
As shown in Figure 1, MSF increased the release of ACh
in a dose-dependent manner. MSF, at 1mg/kg, caused a
signiﬁcant (P<0.05, P<0.01) and prolonged increase ofAdvances in Pharmacological Sciences 3
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Figure 1: Eﬀect of MSF and donepezil on the level of extracellular
ACh in the freely moving rats. Data are expressed as percentage
changes from baseline. Each value represents the mean ± S.E.M.
of ﬁve experiments. Asterisks indicate eﬀects signiﬁcantly diﬀerent
from time course vehicle control (∗P<0.05, ∗∗P<0.01).
ACh eﬄux in the hippocampus from 10 to 180min which
returned to control levels at 24hr after the administration
of MSF. At the higher dose of 2mg/kg, MSF produced a
consistent and proportionately larger increase in ACh release
between 10 to 90min (P<0.01), decreasing progressively
from 120 to 180min (P<0.05, P<0.01) after the
treatment. At 2mg/kg MSF, the elevation of ACh eﬄux
remained elevated at 24hr after injection (P<0.05).
The eﬀects of donepezil on ACh eﬄux are also shown
in Figure 1. A dose of 1mg/kg donepezil produced a small
but consistent increase in ACh eﬄux over the ﬁrst 180
minutes. However, the dose of 2mg/kg did not produce
ad o s e - d e p e n d e n te ﬀect, and ACh eﬄux over the 180min
experiment was not diﬀerent from animals received the dose
of 1mg/kg (data not shown).
As shown in Figure 2, the choline eﬄux decreased
progressively from basal levels throughout the course of the
ﬁrst 180min after injection for every group, MSF, donepezil,
and controls but returned to basal levels by 24hr. The
decreases were less signiﬁcant in the groups that received
MSF or donepezil than in the control group.
The eﬀect of MSF and donepezil on AChE activity in the
hippocampus, striatum, and cortex at 180min (Figure 3(a))
and 24hr (Figure 3(b)) after drug administration is shown
in Figure 3. MSF at 1mg/kg decreased AChE activity in
hippocampus, striatum, and cortex by about 50%, to 55,
51, and 49% of the respective control activities. At 2mg/kg,
MSF produced 80–90% inhibition, bringing AChE activity
to about 20, 12, and 11% of the respective control activities.
Donepezil at 1mg/kg did not produce any signiﬁcant eﬀect
on AChE activity in the three brain regions at 180min
after injection. The dose of 2mg/kg, however, produced a
signiﬁcant decrease in AChE activity in the cortex but not in
the hippocampus or striatum 180min after administration
(Figure 3(a)). Figure 3(b) also shows the brain regional
AChE activity 24hr after 1mg/kg of MSF or donepezil. The
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Figure 2: Eﬀect of MSF and donepezil on the level of extracellular
choline in the freely moving rats. Data are expressed as percentage
changes from baseline. Each value represents the mean ± S.E.M. of
ﬁve experiments.
activityofAChEinthehippocampus,striatum,andcortexof
rats administered MSF was about 44, 36 and 41% (P<0.05
to 0.001) of control values, respectively. At 24hr, no other
signiﬁcant diﬀerences were not observed in the activity of
AChE in any of the three brain regions between the rats
treated with donepezil or vehicle.
4. Discussion
We have previously reported that a single dose of MSF at
1.5mg/kg s.c. signiﬁcantly increased the concentrations of
extraterminal ACh and cytoplasmic ACh in the cortex of
mice [17]. In these experiments, an increase in the fractional
ACh content of brain tissues taken ex vivo and homogenized
for analysis was found to be elevated at 180min, and the
increase persisted to 24hr. The extraterminal ACh deter-
mined in that earlier ex vivo experiment may approximately
correspond to extracellular ACh in the current in vivo exper-
iment at those same time points. The present experiment
conﬁrmed the earlier results and showed that doses of either
1mg/kg or 2mg/kg MSF strongly increase extracellular ACh
during the ﬁrst 180min after administration and the eﬀect
persists for 24hr after the higher dose of 2mg/kg.
Corresponding to the increases in ACh eﬄux found
after MSF, the present study also found that the same doses
reduced AChE activity in the hippocampus to about 55%
and 20% of control 180min after 1mg/kg and 2mg/kg of
MSF, respectively, and to about 44% of control 24hr after
1mg/kgofMSF(theonlydosestudiedat24hr).Theseresults
supportseveralstudiesontheeﬀectsofdrugsforAlzheimer’s
disease that show that increasing levels of extracellular ACh
in various brain regions are found with decreasing AChE
activity [8, 9, 18–22].
Donepezil (1.66mg/kg), rivastigmine (0.4mg/kg), and
huperzine A (more than 0.6 and 3mg/kg) have been found
to increase extracellular ACh in the hippocampus, and the4 Advances in Pharmacological Sciences
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Figure 3: Eﬀect of MSF and donepezil on the activity of AChE in brain regions 180min (a) and 24hr (b) after administration. Each value
representsthemean ±S.E.M.ofﬁveexperiments.Asterisksindicateeﬀectssigniﬁcantlydiﬀerentfromtimecoursevehiclecontrol(∗P<0.05,
∗∗P<0.01).
results are generally not so diﬀerent between the oral or
intraperitoneal administration [8, 18]. All three of these
drugs produced the maximal increase in extracellular ACh
within 3hrs, mostly around 30 to 60min, after adminis-
tration. On the other hand, the present study shows that
MSF increased the level of extracellular ACh for at least
3hrs without showing signiﬁcant peaks. After 2mg/kg MSF,
a signiﬁcant increase was still present at 24hr.
Although donepezil is generally accepted to be eﬀective
in increasing the release of ACh from hippocampus in freely
movinganimals[8,9],thepresentstudy,however,foundthat
donepezil succeeded in increasing extracellular ACh only at
a dose of 1mg/kg. Surprisingly, it failed to demonstrate a
dose-dependent eﬀect at a dose of 2mg/kg. Although the
doses of donepezil, 1mg/kg and 2mg/kg, were selected for
comparison to the MSF results, a possible explanation for
our failure to ﬁnd a dose-dependent eﬀect of donepezil
on extracellular ACh may be that the dose of 2mg/kg was
not suﬃciently greater than the 1mg/kg dose to produce
ac l e a rd i ﬀerence. The dose-dependent eﬀects of donepezil
on increasing the level of extracellular ACh in the striatum
achieved by previous reports [18] were obtained by using
doses at 1, 3, and 5mg/kg.
In the present study, donepezil at doses of 1 and 2mg/kg
did not show any signiﬁcant inhibitory eﬀect on the activity
of AChE in the hippocampus at 180min after administration
(Figure 3(a)). Donepezil is a reversible AChE inhibitor [9,
23]andtheAChEinhibitionitproducesmaydisappearwhen
the tissues are homogenized as the donepezil will be diluted.
5. Conclusions
The present study showed that MSF at doses 1 and 2mg/kg
produced a consistent increase in the eﬄux of ACh in freely
moving rats as measured by microdialysis throughout the
ﬁrst 3hrs at both doses and a persistent increase was still
present at 24hr at the higher dose. Since ChE inhibitors
are the major therapeutic agents used in AD patients, the
agent-like MSF, which increases extracellular ACh in the
hippocampus with a long-lasting eﬃcacy but without excess
stimulation, may serve as an eﬀective therapy to alleviate or
prevent the central cholinergic deﬁcits which are reported to
cause cognitive impairments.
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